Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for HypertensionAccesswire • 09/08/21
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP ReductionBenzinga • 09/07/21
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension PatientsBenzinga • 09/07/21
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory PeriodAccesswire • 09/07/21
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery TechnologyBenzinga • 09/02/21
Lexaria Hits New 52-Week High With Positive Data On Enhanced Treatment For COVID-19Seeking Alpha • 07/22/21
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3Accesswire • 07/21/21
Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization StudyBenzinga • 07/15/21
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research CouncilAccesswire • 07/15/21
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital MarketsAccesswire • 07/05/21
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)Newsfile Corp • 06/17/21
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral DrugsAccesswire • 06/15/21